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LIST OF SYMBOLS AND ABBREVIATIONS 
 
OAG  open-angle glaucoma 
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The trabecular meshwork (TM) is a structure in the eye responsible for the 
drainage of aqueous humor. Due to the reduced cellularity found in the TM during 
glaucoma, TM function is reduced, resulting in elevated intraocular pressure. Stem cell 
therapies could provide a novel treatment option if cell delivery can be targeted to the 
TM. The purpose of this study is to determine if delivery of stem cells, labeled with 
Prussian blue magnetic nanocubes, delivered to the TM can be enhanced with magnetic 
field application. For delivery experiments, anterior segments of porcine eyes, were 
maintained in organ culture and perfused at physiological flow rates. Stem cells labeled 
with magnetic nanoparticles were injected intracamerally and steered to the TM region 
with a magnetic field. Confocal fluorescent imaging showed an increase in the delivery of 
stem cells to the TM when compared to control with no magnet. This novel technique for 
delivering stem cells may allow for future research into cell therapies for glaucoma which 
directly target the TM. Such a treatment could benefit the millions of individuals who 
suffer from glaucoma. 









 Glaucoma is a group of eye-related disorders that lead to optic nerve damage and 
eventual vision loss (1). Open-angle glaucoma (OAG), the most common form of 
glaucoma, is caused by an increase in resistance to the drainage of aqueous humor (AH) 
through the trabecular meshwork (TM) and Schlemm’s canal (SC)(1). This increased 
resistance results in elevated intraocular pressure (IOP), damaging the optic nerve, and 
leading to vision loss. Although a majority of AH drains through the TM/SC, known as 
the “conventional route”, current glaucoma treatments do not directly target this route(2). 
Instead, drugs either decrease the production of AH or increase flow through the 
unconventional pathway, which normally only accounts for approximately 10% of AH 
drainage(1). Thus, methods that target the primary outflow path of AH would be 
beneficial for the treatment of glaucoma. 
 TM cells are crucial for the regulation of IOP through modulation of AH drainage 
resistance, possibly due to constriction or relaxation of the tissue(2). The cellularity of the 
TM decreases throughout a person’s life, up to 60% by age 80(3).  The remaining TM 
cellularity can be further reduced by 30% in cases of glaucoma(4). This loss in cellularity 
likely prevents the TM from properly functioning, resulting in increased resistance, 
increased IOP, increasingly worse optic nerve damage, and eventual vision loss. 
Therapies that aim to reintroduce functional TM cells to the TM have the potential to 
restore the tissue’s ability to properly modulate IOP. To restore TM cellularity, a variety 
of stem cell sources, such as adipose derived mesenchymal stem cells (ADSCs), and 
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induced pluripotent stem cells (iPSCs), have been used and shown to have the potential to 
differentiate into functional TM cells(5, 6). Injections of stem cells into the anterior 
chamber in various animal models of glaucoma have been shown to reduce IOP(5, 7, 8). 
However, delivery of stem cells to the TM has been inefficient and, of the delivered cells 
to the TM, the cells were not consistently retained in the TM for prolonged periods of 
time, necessitating an enhanced cell delivery method.  
One challenge in cell delivery to the TM is that drainage of AH is naturally 
segmental. At any given time, only approximately one third of the TM region is 
experiencing flow. As a result, a large majority of injected cells or particles concentrated 
in that third of the TM(2).  It is thought that the actively filtering regions of the TM 
fluctuate, so cell delivery to all portions of the damaged TM circumference is crucial for 
glaucoma therapies. However, this is not possible with passive cell delivery. A method is 
needed to ensure that the cells will be delivered to the entire circumference of the TM 
instead of congregating only in active filtering regions. In addition, it is important to 
prevent non-specific delivery to other anterior tissues during stem cell delivery. Stem cell 
attachment to non-target tissue such as the lens and cornea, has the potential to damage 
these tissues and impact vision. A method to enhance cell delivery to all regions of the 
TM while preventing off-target delivery is needed to further study the regenerative 
potential of stem cells in glaucoma.  
 To enhance stem cell delivery, we used magnetic nanoparticles. These 
nanoparticles have been utilized for many different regenerative medicine applications, 
such as enhancing tissue penetration of drugs or cells to a target tissue by utilizing 
magnetic fields(9). This study seeks to utilize Prussian blue Nanocubes (PBNCs), a type 
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of magnetic nanoparticle comprised of  superparamagnetic iron oxide nanoparticles and 
Prussian blue dye which allows for visual detection of particles(10). Stem cells will be 
labeled with an optimized concentration of PBNCs, as determined by cell viability and 
function assessment. Labeled stem cells will then be injected into anterior segments of 
porcine eyes cultured in perfusion dishes to assess if cell delivery to the TM is enhanced 
with a magnetic field. Specifically, to determine if the injected cells are pulled evenly to 
the entire circumference of the TM. A method resulting in an even distribution of stem 
cells delivered to the TM will aid in the creation of a glaucoma treatment that specifically 






Glaucoma affects over 70 million people worldwide and is the second leading 
cause of blindness(2). Many glaucoma treatments aim to decrease the production of AH 
or increase uveoscleral outflow in order to decrease the elevated IOP which is causing 
damage to the eye(1). Currently, there are no treatments that directly target the TM, the 
main structure which controls IOP. Stem cells can potentially be used to repopulate and 
return function to the partially decellularized TM in glaucomatous eyes(3, 5). However, 
delivering stem cells to the TM with minimal non-specific binding and for long durations 
needs to be optimized.  
Pluripotent vs. Multipotent Stem Cells 
Stem cells are an immature cell type which self-renew and have the capacity to 
differentiate into other cell types(11). Stem cell self-renewal allows them to indefinitely 
proliferate to more cells of the same type. The key function of stem cells is maturation, or 
differentiation, to other cell types found throughout the body(12). Totipotent stem cells 
have the potential to differentiate into any type of adult cell as well as embryological 
tissue(13). Pluripotent stem cells have the ability to differentiate into any type of adult 
cells and are harvested from embryos, known as embryonic stem cells, or reprogrammed 
from adult somatic cells, known as iPSCs (14-16). Some stem cells are more limited in 
the types of cells that they can differentiate into. These are called multipotent stem cells. 
Multipotent stem cells are found throughout the body, but are generally isolated from 
either bone marrow or adipose tissue(11). There are two main types of multipotent stem 
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cells: mesenchymal and hematopoietic. Mesenchymal stem cells can differentiate into a 
variety of tissue cell types while hematopoietic stem cells differentiate into blood 
cells(11, 17). Although multipotent stem cells are more restricted in the types of cells 
they can differentiate into, they are a great resource for regenerative therapy studies. 
Multipotent stem cells can be autologous, meaning that the cells can be harvested from 
the individual who will be receiving the treatment which reduce the chances of 
rejection(11). ADSCs are especially useful due to the ease of harvesting and abundance 
of cells obtained at each harvest. Unlike pluripotent stem cells, ADSCs are also non-
tumorigenic, meaning they do not have the risk of forming tumors when they are injected 
into the body; this makes them more attractive for translational clinical studies(11, 14). 
Recent Advances in Stem Cell Delivery to the TM 
One of the most common issues with current stem cell delivery is a lack of 
specificity in tissue engraftment(18). For delivery to the TM, off-target cell integration 
could be detrimental to other structures within the anterior chamber of the eye, such as 
the lens. According to a study done in mice utilizing iPSCs, off-target integration was 
observed in the endothelial layer of Schlemm’s canal and on the corneal epithelium and 
stroma, especially in the area directly surrounding the injection site (6).  The iPSCs used 
in this study were first differentiated into iPSC-TM cells, cells resembling functional TM 
cells, before injection (6). To avoid tumor formation due to pluripotent cells, iPSC-TM 
cells must be purified from non-differentiated cells prior to injection. If this purification 
process is not 100 percent successful, tumors may form due to the presence of cells that 
still retain their pluripotent nature. As a simpler alternative, multiple studies have used 
adipose tissue as a source of multipotent stem cells capable of differentiating into TM 
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cells (11, 12). A method that increases delivery efficiency and reduces the non-specific 
binding of the injected cells is needed to prevent possible damage to anterior chamber 
structures. 
Roubeix et al. found that the distribution of mesenchymal stem cells (ADSCs) is 
not equal throughout the entirety of the TM (7). Despite this uneven cell delivery, they 
still observed IOP reduction after ADSC delivery(7). However, delivery to the entirety of 
the TM may be essential for therapies. In addition, in this study, IOP was only measured 
every 3-4 days(7). This low sampling rate allows for important information to be missed 
between measurements. A method that records IOP more frequently would provide more 
complete data. 
According to a study by Manuguerra-Gagne et al.(8), ADSCs injected into the 
anterior chamber of murine eyes were no longer detectable after 96 hours. This study 
created a glaucoma model by using a laser to damage portions of the TM to represent the 
loss of cellularity which occurs in glaucoma(8). The authors found that the injected 
ADSCs were able to successfully migrate to the area of damaged tissue but did not 
remain in the anterior chamber for a prolonged period of time(8). Thus, it may follow that 
a method to increase survival of cells in the TM as well as a method to specify their target 
region without further damage to the TM is needed. 
Potential of Magnetic Nanoparticles 
Magnetic nanoparticles are beginning to emerge as a useful tool for regenerative 
medicine (9). They can be utilized to improve target specificity and enhance penetration 
of cells into tissues(9). Many types of magnetic nanoparticles have been shown to be 
nontoxic to cells and suitable for intraocular use(19, 20). Therefore, it is possible that 
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nanoparticle-labeled stem cells can be used to specifically target the TM and increase 
penetration into the TM. Ideally, this will enhance stem cell retention in the tissue. In 
addition, it is possible to detect magnetic nanoparticles using ultrasound and 
photoacoustic imaging(21). Ultrasound can be used to non-invasively image by aiming 
high frequency sound waves at objects and interpreting the waves that return to the 
transducer. Photoacoustic imaging pairs with standard ultrasound by using a laser to 
energize photoabsorbers, such as many different dyes and pigment, which causes them to 
expand and produce sound waves detectable by ultrasound. This would be useful for 
obtaining images of the injection process and for tracking cell delivery in real-time. 
 This study seeks to utilize Prussian blue nanocubes(PBNCs) (10), a type of 
magnetic nanoparticle, along with ADSCs to enhance cell engraftment to the TM. An 
optimal concentration of PBNCs will be determined based on cell viability and 
proliferation. After this concentration is determined, ADSCs will be labeled with the 
PBNCs and injected into the anterior segment of porcine eyes set up in custom-built 
organ culture dishes where they will be perfused at physiological rates. We will then use 
a ring magnet to guide the injected cells to the TM. We hypothesize that this method will 
allow for ADSC delivery to the entire TM circumference as well as increase the 
penetration of the cells into the target tissue. The organ-cultured eyes will be connected 
to pressure transducers and a computer which records data each minute throughout the 
entirety of the experiment. This method of stem cell delivery overcome delivery 
heterogeneity and lessens off-target delivery since most of the cells pull to the correct 






 Fully characterized human ADSCs from Lonza were grown in α-minimum 
essential medium supplemented with 20% fetal bovine serum (FBS), penicillin, 
streptomycin, and L-glutamine. In all experiments, ADSCs are used at passage numbers 
five or six. 
PBNC and Fluorescent Stem Cell Labeling  
ADSCs were labeled with 200nm PBNCs by incubating with different optical 
densities (ODs) of PBNCs ranging from 0 to 2 OD overnight in a 37o C incubator. Before 
delivery, cells were fluorescently labeled with CFSE (carboxyfluorescein succinimidyl 
ester). To do this, cells were detached with 0.05% Trypsin/EDTA and resuspended in 
5uM CFSE (2mL for ~ 1million cells) for 15 minutes at 37o C. High serum media (20% 
FBS, 6mL for ~1million cells) was then added to quench unreacted CFSE.  
Porcine Eye Dissection 
 Fresh porcine eyes, sourced from a slaughterhouse, were used within 6-8 hours of 
enucleation. First, orbital connective tissue was removed, and eyes were soaked in 
Betadine solution for 5 minutes. Following Betadine immersion, eyes were transferred to 
a sterile laminar flow hood for the remainder of the process. Eyes were hemisected with a 
razor blade to isolate the anterior segment. The vitreous humor and lens were removed, 
the iris was dissected back until the TM was revealed, and the ciliary processes were 
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carefully removed while preserving the TM. Any additional vascularized, pigmented 
tissue was then removed.  
Porcine Eye Perfusion 
Dissected eyes were placed in a custom-designed organ culture dish (Figure 1 A) 
and secured in place with a ring clamp (Figure 1 B). The dishes containing the eyes were 
placed in a 37o C incubator and perfused at 2.5 uL/min with serum-free media containing 
1x penicillin, streptomycin, and amphotericin while pressure was recorded through 
transducer readings in LabView (Figure 1 C). Eyes were allowed to stabilize for at least 
48 hours before conducting any experiments. Any eyes whose outflow facility was 
unable to stabilize between 0.45 and 0.125 uL/min/mmHg (~6mmHg to 20mmHg IOP) 





































Figure 1. Organ Culture Set Up. (A) Cross section of a custom-built organ culture 
dish. (B) Anterior segment of a porcine eye clamped into an organ culture dish. (C) 
Example outflow facility data retrieved from pressure transducer readings. 
 
ADSC injection into Porcine Eyes 
 250,000 ADSCs (1 million cells/mL) were injected through the center of the 
cornea while eyes were hydrostatically clamped at 8 to 12 mmHg. A neodymium bar 
magnet (1” L x 0.25” W x 0.25” H) was used to apply a magnetic field to one quadrant of 
the TM for either 15 minutes, 30 minutes, 60 minutes, or overnight.  
 For other experiments, ring magnets were used for delivering stem cells to the 
entire TM circumference. Two different rings magnets were used. First, a model which 
houses 10 cylindrical neodymium magnets arranged in a ring and can be set up in the 
organ culture dishes was constructed in SOLIDWORKS and 3D printed. Second, a 
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commercially available axially polarized ring magnet was used. After delivery, eyes were 
then formalin fixed. 
Image Processing 
After fixation, the sclera was trimmed close to the TM region and placed in a 
glass bottom 50mm dish for en face imaging of the anterior segment. Micrographs of the 
entire TM circumference were captured by confocal microscopy (Carl Zeiss, Germany) to 
identify delivered CFSE-tagged ADSCs in the TM region. Brightfield overlays were also 
captured to note the corneal region and approximate TM location. Micrographs were 
captured as tile scans at 50x magnification and with z-stacks to account for TM depth and 
height differences in the tissue. Maximum intensity projections were developed for each 
en face image for use in further image quantification.  
To determine the TM region for quantification, masks were created from 
brightfield images using the corneal region as a landmark. A 1mm-wide ring from the 
edge of the cornea mask was selected as the TM region for each image using ImageJ(22, 
23). Images were further processed in Matlab (MathWorks) to remove large fluorescent 
debris greater than 100 µm. An example of this image analysis can be seen in Figure 2. 
To quantify fluorescent intensity across the TM circumference, a polar coordinate system 
was overlaid onto images and the total CFSE intensity was quantified for each degree. 
Intensities were then summed for each 10 degrees, resulting in 36 intensity values for 
each image. The process was repeated for non-masked fluorescent images when 



























Figure 2. Image Processing Overview. (A) Raw fluorescent en face micrographs showing 
CFSE-labeled ADSCs. (B) Brightfield en face images used for determining the TM location. 
Masks were constructed from brightfield images and 1mm wide rings were used to 
determine (C) the TM tissue region. (D) Large fluorescent debris was excluded using 
Matlab before further image processing. 
 
Cell Viability Testing 
 After cells were labeled with PBNCs as described above, they were stained with 
propidium iodide in PBS for 5 minutes at room temperature. Then, cells were detached 
with 0.05% trypsin/EDTA and placed in a 96-deep well plates. Cell samples were 
processed by flow cytometry (Attune NxT), collecting equal volumes from each sample. 
Living cell concentrations were determined and compared to control concentrations to 






 To determine if the PBNCs interfere with the ADSCs’ ability to differentiate, 
ADSCs were incubated with PBNCs at ODs ranging from 0 to 2. Then, adipogenic 
differentiation medium or osteogenic differentiation medium was added.  
After 7 days, the cells cultured in adipogenic differentiation medium were stained 
with Nile Red to measure lipid build-up indicating the stem cells had successfully 
differentiated. Cells were incubated for 5 minutes with 100 ng/mL Nile Red in PBS. 
Afterwards, cells were washed and probed with DAPI (Life Technologies) which 
fluorescently stains cell nuclei. For each cell sample, 16 fluorescent micrographs were 
captured in an array across each well using an imaging plate reader (BioTek, Cytation 3) 
and stitched together.  Nile Red average fluorescent intensities were quantified for each 
image and normalized to DAPI cell counts. Further, adipogenesis was qualitatively 
assessed by Oil Red O staining(24). 
After 21 days, the cells exposed to osteogenic differentiation medium were 
stained with Alizarin Red to stain for extracellular calcium indicating successful 
differentiation into an osteoblast phenotype. Cells were stained with 2% (w/v) Alizarin 
Red for 2 minutes followed by PBS rinses to remove excess dye. Experiments were 
qualitatively assessed by light microscopy followed by counterstaining cell nuclei with 




  All in vitro studies were performed in triplicate. Analysis of variance was used to 
determine significance in cell experiments, where p-values less than 0.05 denote 
significance.  
For all time points tested for cell injections, N is specified. To assess for non-
uniform circular distribution towards the rectangular magnet location, Kuiper’s test was 
performed on average results and p-values less than 0.05 indicate aggregation near the 
magnet location. For ring magnet experiments, Rayleigh’s test for uniform circular 
distribution was calculated for average results and p-values less than 0.05 indicate non-







Proof of ADSC Labeling with PBNCs 
 To confirm that ADSCs were successfully labeled with PBNCs, cells were 
incubated with 200nm PBNCs overnight, were eosin (cytoplasm) stained, and imaged 
using an EVOS microscope (Figure 3). Images show blue PBNCs within the cytoplasm 
of the cells for all optical densities tested. 
 
 
Cell Viability Results 
 Flow cytometry data was gathered after propidium iodide staining two different 
ADSC donor strains which were labeled with PBNCs overnight (Figure 4). Data obtained 
was normalized to the data obtained from non-treated control cells. ADSC B showed 
decreased cell viability at 4 OD PBNC incubation but lower ODs showed minimal 
Figure 3: ADSCs labeled with PBNCs. Representative brightfield micrographs 
for ADSCs after incubation with different PBNC sizes and concentrations. 
ADSCs are eosin stained to visualize cytoplasm while PBNCs are in blue. (A) 
Control, (B) 2 OD, 200nm PBNC, and (C) ½ OD, 200nm PBNC. 
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viability effects. ADSC A did not have any significant decrease in cell viability at any of 




Two types of ADSCs were labeled with 200 nm PBNCs and exposed to 
adipogenesis differentiation medium for 7 days. Oil Red O staining revealed lipid 
droplets inside of the cells when imaged for all optical densities as well as the 
control (Figure 5 A-C). The relative fluorescence when compared to untreated 
controls is similar, indicating little difference in differentiation between control 
and treatment results (Figure 5 D). 
 
 
Figure 4: Live-Dead Results for 200nm PBNC labeled ADSCs. Relative viability 
results 1 day after PBNC labeling for 2 ADSC donor strains (n=3 for each OD). 





Two types of ADSCs were labeled with 200 nm PBNCs and exposed to 
osteogenic differentiation medium for 21 days. Alizarin Red O staining revealed 
extracellular calcium when imaged for both optical densities as well as the control 
(Figure 6 A-C). The relative fluorescence data compared to the untreated controls 
is 1 or more for each of the cells types tested, indicating little difference in 
differentiation between control and treatment results (Figure 6 D). 
 
 
Figure 5: Effect of 200nm PBNCs on ADSC adipogenic potential. (A-C) Oil Red 
O (lipids) staining for (A) 4OD 200nm PBNC, (B) 1 OD 200nm PBNC, and (C) 
control wells 7 days after adipogenesis treatment. (D) quantification of ratio of 
fluorescent Nile Red (lipids) to DAPI (nuclei) signal relative to untreated controls 







Delivery of PBNC-labeled cells 
 After ADSC delivery and bar magnet exposure, en face micrographs were taken 
of the TM region. A polar coordinate system was overlaid for each resulting image 
(Figure 7 A). The region of the TM that was exposed to the bar magnet is centered at 0 
degrees. There is much higher fluorescence seen in the magnetic quadrant following 
PBNC-ADSC delivery in comparison to the controls (Figure 7 A-B).  
Figure 6: Effect of 200nm PBNCs on ADSC osteogenic potential. (A-C) Alizarin Red O 
(calcium) staining for (A) 4OD 200nm PBNC, (B) 1 OD 200nm PBNC, and (C) control 
wells 21 days after osteogenesis treatment. (D) quantification of ratio of fluorescent 
Alizarin Red (lipids) to DAPI (nuclei) signal relative to untreated controls for 2 stem cell 





Quantification of Overnight Cell Delivery 
 A Kuiper’s test was performed on the overnight magnet exposure cell delivery 
images (Figure 8) to determine if there was significantly more delivery to the regions 
exposed to the magnet (0o region) in comparison to the other regions. Specifically, if the 
region exposed to the magnet had a higher fluorescent intensity. The control ADSC 
injected eyes had a p > 0.05 and was therefore not significant. The 200nm 2 OD PBNC 
labeled cells each had p < 0.001 and were therefore significant. 
 
 
Figure 7: 200nm PBNCs for magnetic ADSC steering.  Representative en face 
micrographs of the TM region following ADSC delivery and bar magnets secured 
overnight at 0o near the limbal region. CFSE-tagged MSCs (Green) were pre-labeled 




Cell delivery via ring magnet 
After 2OD labeled PBNC-ADSCs were injected into eyes and then exposed to 
different ring magnets placed around the entire circumference for different durations, en 
face micrographs were taken of the TM region. Fluorescence shows cell delivery to the 
entire circumference of the TM for the eyes exposed to ring magnets (Figure 9 B-D) but 






Figure 8: Quantification of ADSC delivery to the TM for 200nm PBNCs. Polar 
histograms illustrate ADSC fluorescent intensity (radial coordinate) for each 30o region, 
in which the bar magnet was place at 0o overnight. Average results (A) 200nm PBNCs at 
2OD (n=4 eyes), and (B) control (n=5 eyes) experiments are shown. P-values were 





Quantification of 360o cell delivery 
A Rayleigh’s test was performed on the ring magnet exposure cell delivery 
images (Figure 10) to determine if delivery was not normally distributed around the 
circumference, which would indicate an uneven cell delivery. The axial polarized ring 
magnets had p > 0.05 which suggesting even cell delivery (Figure 10 C-D). The Control 
and 3D printed custom ring magnet both had p < 0.05 indicating uneven cell delivery to 
the TM (Figure 10 A-B). 
 
 
Figure 9: 360o Delivery of PBNC-ADSCs using ring magnets. 200nm, 2OD labeled 
PBNC-ADSCs were injected into eyes with different ring magnets placed around the 
entire circumference for different durations. Representative en face micrographs for (A) 
control, (B) 3D-printed magnet holder for 30 minutes, (C) axially polarized ring magnet, 





Figure 10: Quantification of ADSC delivery for ring magnet experiments. Polar 
histograms illustrate ADSC fluorescent intensity (radial coordinate) for each 30o region. 
Average results for (A) control (n=5 eyes), (B) custom-built magnet holder for 30 
minutes (n=3 eyes), (C) axial polarized ring for 15 minutes (n=3 eyes), and (D) axial 
polarized ring for 30 minutes (n=3 eyes) experiments are shown. P-values were 







 The treatment of glaucoma could be greatly aided by a method to enhance 
stem cell engraftment to the TM for the purpose of restoring cellularity and presumably 
function. Restoring function to the TM would reduce resistance to AH flow and lower 
IOP, preventing further damage to the optic nerve. Such a method, which aims to impact 
the TM directly, does not currently exist. The goal of this thesis was to explore whether 
ADSCs which have been labeled with PBNCs can be directly targeted to the TM via 
magnetic field exposure. 
For PBNCs to be a viable option for enhancing stem cell engraftment into the 
TM, they must successfully label cells. The results of the labeling experiments proved 
that PBNCs can enter ADSCs without prior permeabilization of the cell membrane 
(Figure 3). The PBNCs must also be biologically compatible with ADSCs so as not to 
interfere with differentiation or survival. Cell viability testing revealed that there was not 
significant loss in cell viability after labeling with PBNCs at the concentrations that were 
necessary to allow for the cells to be influenced by magnetic fields (Figure 4). 
Regenerative stem cell therapies depends on stem cells differentiating into 
functional cells once they are delivered to the target tissue. Therefore, it is imperative that 
the PBNCs do not impede the ADSCs ability to differentiate. Adipogenesis and 
Osteogenesis assays were performed on cells that had been labeled with PBNCs (Figures 
5-6). The results indicate that the ADSCs labeled with the nanoparticles were able to 
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successfully differentiate into both cell types to the same degree as the control cells. 
Overall, the tests performed for this study indicate that PBNCs can label ADSCs without 
affecting cell viability or differentiation. As a result, ADSCs labeled with PBNCs have 
the potential to be used for regenerative therapies.  
Once the PBNCs had been proven to be compatible with ADSCs, we tested 
whether PBNC-labeled ADSCs could targeted to the TM. The cell delivery experiments 
indicate that PBNCs have the potential to enhance stem cell engraftment into the TM. 
The overnight bar magnet exposure showed that the region which was exposed to the 
magnet had significantly more fluorescent cell signal when compared to the rest of the 
TM region (Figure 8). This indicates the ADSCs labeled with PBNCs were successfully 
pulled to the TM region at a higher efficiency that standard delivery conditions. This 
proves that it is possible to use magnetic fields to direct more ADSCs to the TM 
compared to simply injecting ADSCs into the anterior chamber and allowing AH outflow 
bring cells to the TM. In addition, the ability to inject less cells decreases the number of 
instances in which off target binding to the cornea may occur. This decreased chance for 
off target delivery is important when considering the viability of this method as a 
potential glaucoma treatment option. If there were to be a significant amount of corneal  
or lens cell delivery, the ADSC therapy could worsen an individual’s vision rather than 
helping to prevent further vision loss. 
 Loss of cellularity throughout the entirety of the TM occurs with both aging and 
glaucoma. In order for a stem cell therapy to restore function to the largest portion of the 
TM possible, stem cells need to be delivered to the entire circumference. Relying solely 
on AH outflow to deliver the cells results in delivery to only active portions of the TM 
during the time of delivery. These active segments are variable and are decreased in the 
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case of glaucoma (25). The results from the axial polarized ring magnet experiments 
indicate that uniform ADSC delivery to the entire circumference of the TM is possible. 
However, to prevent corneal binding, a better ring magnet needs to be created to more 
specifically aim the magnetic fields to the TM. To avoid directing cells to the cornea, a 
radially pulling ring magnet would be preferred. However, the 3D printed custom ring 
magnet used in this experiment resulted in non-uniform delivery of ADSCs to the TM 
circumference, so in order to optimize the magnetic field configuration of the ring 
magnet, further testing and refinement is needed. 
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 CHAPTER 5 
CONCLUSIONS 
 
 A therapy that directly targets the main route of AH flow in order to treat OAG 
does not yet exist. Stem cell therapies are a promising method to restore function and 
cellularity to the glaucomatous TM. In addition, using magnetic fields to allow delivery 
to the entire circumference of the TM will prevent cells from being delivered to the active 
third (or less in the case of glaucoma) of the TM and give a more adequate repair (25). 
Results from these studies show PBNCs are nontoxic to ADSCs at concentrations 
that allow them to be pulled via magnetic fields. Further, PBNCs do not impair ADSCs 
ability to differentiate. Using PBNCs, ADSCs can be delivered to the TM at a higher 
efficiency compared to control, no magnet delivery experiments. Interestingly, PBNCs 
can be used to ensure an even delivery to the entire circumference of the target tissue, 
which may be essential for properly recellularizing the TM.  
Future studies need to be done for determining why toxicity of the PBNCs in on 
ADSCs was different across cell strains. In addition, a better ring magnet design for 
pulling cells specifically to the TM needs to be developed to stop nonspecific binding of 
stem cells to other ocular tissues. Next steps will also involve assessing delivery in vivo 
so that other relevant anterior tissues, such as the lens and iris, can be incorporated into 
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